Home › Companies › HELP

Helus Pharma

Market cap $575M 79.8M shares (vendor count, Nov 18, 2026) × $7.20 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Pipeline (3 active programs)

Discontinued (1)

Capital (as filed)

As stated in coverage
$171M cash, runway 4Q 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (15)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (15 calls)

Every verdict Biotech Distilled has published on Helus Pharma, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Helus Pharma (HELP), formerly Cybin (CYBN): Scientific Deep Dive for HLP003 and Pipeline Products The company is a leveraged binary bet on FDA acceptance of psychedelic trial designs with a terrifying 1:1 cash-to-burn ratio; wait for ATM dilution to depress the price before entering.
  2. Watch UPDATE: Helus Pharma (HELP): The Big Guns Arrive Point72's 6.2% stake and Michael Cola's commercial CEO appointment de-risk the business side, but the Dilution Gap and functional unblinding risk remain; watch for HLP004 data reaction before acting.
  3. Buy speculative UPDATE: Helus Pharma (HELP) - The Smart Money Tug-of-War & Peer-Reviewed Receipts OrbiMed's arrival and Nature Medicine publication of the DMT mechanism upgrade scientific conviction, but the imminent HLP004 data readout is the tie-breaker; trade the volatility but respect the dilution risk.
  4. Hold UPDATE: Helus Pharma (HELP) - The Big Pharma Makeover is Complete Former Pfizer CMO joining the board reinforces M&A appeal and regulatory de-risking, but the HLP004 data readout remains the imminent catalyst before any position change.
  5. Avoid UPDATE: Helus Pharma (HELP) - The Pooled Data Trick and the $5.25 Reality Check HLP004 Phase 2 data was massaged by pooling active and placebo arms to hide weak remission differentiation, fundamentally breaking the HLP004 thesis and making the HLP003 Phase 3 risk profile radioactive.
  6. Watch UPDATE: Helus Pharma (HELP) - Izzy Englander Buys the Dip Millennium Management's 4.8% stake alongside Point72 and OrbiMed signals blue-chip institutional conviction in the M&A/event-driven thesis, reducing catastrophic-zero risk before the Q4 2026 readout.
  7. Watch UPDATE: Helus Pharma (HELP) - Cola Gets the Boot, Trump Signs the EO, Millennium Doubles Down The Executive Order mandating prioritized FDA review and DEA rescheduling for BTD psychedelics is the biggest regulatory tailwind ever for the sector, but the +24% rip already prices it in and CEO churn 8 months before the binary readout warrants caution on entry.
  8. Watch UPDATE: Helus Pharma (HELP) - Point72 Trims, Sirenia Arrives, Stock Bleeds Point72 trimming from 6.2% to 1.4% materially weakens the 'Adults in the Room' sponsorship thesis, while the unknown Sirenia replacement and a vacant permanent CEO seat keep the risk/reward ambiguous.
  9. Watch UPDATE: Helus Pharma (HELP) - The Dilution Lands, And It's Not the ATM The $50M bought deal at a 4.7% discount cleanly addresses the Dilution Gap and signals real institutional demand, but post-raise digestion and a still-vacant permanent CEO seat argue for waiting before entering.
  10. Speculative buy speculative UPDATE: Helus Pharma (HELP) - The +35% Rip, the Definium Footnote, and EMBRACE Enters the Chat The dilution setup has substantially played out with the $50M bought deal cleared, EMBRACE Phase 3 disclosed with a 2028 NDA target, and the institutional roster sized in; the asymmetric binary setup is now legible, though chasing $6.88 is not the trade.
  11. Speculative buy speculative UPDATE: Helus Pharma (HELP) - APPROACH Enrollment Done, The Binary Event Is Now a Data Question APPROACH enrollment completed ahead of schedule at 223 patients with 1:1 randomization, retiring enrollment risk and confirming the Q4 binary event is on the rails, though chasing $8.10 on mechanical re-rating is not the trade.
  12. Speculative buy speculative UPDATE: Helus Pharma (HELP) - A Permanent CEO, a Clean DDI Study, and 11 Million New Shares The permanent CEO hire (ex-Intra-Cellular President) and clean DDI study retire the two remaining execution risk flags, but the +48% move to $11.99 has compressed the asymmetry and an 18% share-count increase via equity comp warrants caution on new entries.
  13. Speculative buy speculative UPDATE: Helus Pharma (HELP) - The Founders Leave the Room Founders stepping back to independent roles and a banker becoming independent Chair completes the Big Pharma Makeover governance transition, reinforcing M&A appeal ahead of the Q4 readout, though the ATM remains live and the entry at $10.52 still requires a strong effect size.
  14. Hold UPDATE: Helus Pharma (HELP) - The Smart Money Thins Out Before the Coin Flip Millennium trimming from 5.7% to 1.4% (following Point72's similar exit) strips the institutional sponsorship anchor from the thesis, while insider equity comp has grown the share count 55% since March; with the readout weeks away, holders should size for a d≈0.4 outcome being survivable rather than adding.
  15. Speculative buy speculative UPDATE: Helus Pharma (HELP) - The Coin Lands Heads, and the Stock Sells Off Anyway APPROACH Phase 3 hit every endpoint with a clinically meaningful 7.6-point MADRS gap (d=0.65) and durability to Week 12, retiring first-pivotal clinical risk; the -13.5% sell-the-news drop to $7.67 offers a better entry on a de-risked asset ahead of EMBRACE replication in 4Q 2027.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (7 quotes from 7 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (71)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 1, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

19 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)